Prevalence of and Among Eritreans and Its Potential Impact on Artesunate/Amodiaquine Treatment

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2020 Nov 19

PMID 33209048

Citations 3

Authors

Lidia Habtemikael

Mulugeta Russom

Iyassu Bahta

Selam Mihreteab

Araia Berhane

Andreas Martensson

Jose Pedro Gil

Affiliations

Soon will be listed here.

Abstract

Background: In Eritrea, artesunate-amodiaquine is the first-line treatment against uncomplicated malaria. Amodiaquine, which is mainly bio-transformed by CYP2C8, is known to be associated with adverse events of different severity. Extrapyramidal events are among the less common but have been reported with non-negligible frequency in Eritrea. This study was conducted to investigate the allele frequencies of and , both associated with decreased amodiaquine metabolism, among the Eritrean population.

Methods: During September-November 2018, dried blood samples from 380 participants and 17 patients who previously had experienced extrapyramidal symptoms following treatment of artesunate-amodiaquine were collected and PCR-RFLP genotyped for and .

Results: The allele frequencies of and were determined as 5.9% (95% CI: 4.4-7.8) and 4.6% (95% CI: 3.2-6.3), respectively. Four out of the 17 patients with extrapyramidal reactions showed to be carriers of the alleles.

Conclusion: and frequencies among Eritreans were found to be intermediate between the documented for Caucasian and African populations. These findings, along with the alleles not being decisive for the occurrence of extrapyramidal events, might be of importance regarding the amodiaquine-containing malaria treatment in Eritrea. Furthermore, it suggests a significant proportion of slow amodiaquine metabolizers in the Sahel region, information of potential interest in the context of amodiaquine-involving seasonal malaria chemoprevention.

Citing Articles

The Influence of Cytochrome P450 Polymorphisms on Pharmacokinetic Profiles and Treatment Outcomes Among Malaria Patients in Sub-Saharan Africa: A Systematic Review.

J Marwa K, Kapesa A, Kamugisha E, Swedberg G Pharmgenomics Pers Med. 2023; 16:449-461.

PMID: 37223718 PMC: 10202199. DOI: 10.2147/PGPM.S379945.

Current situation of fungal diseases in Eritrea.

Werkneh S, Orefuwa E, Denning D Mycoses. 2022; 65(8):806-814.

PMID: 35633079 PMC: 9545796. DOI: 10.1111/myc.13474.

Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar.

Pernaute-Lau L, Morris U, Msellem M, Martensson A, Bjorkman A, Gil J Malar J. 2021; 20(1):90.

PMID: 33588856 PMC: 7885591. DOI: 10.1186/s12936-021-03620-6.

References

Cavaco I, Martensson A, Froberg G, Msellem M, Bjorkman A, Gil J . CYP2C8 status of patients with malaria influences selection of Plasmodium falciparum pfmdr1 alleles after amodiaquine-artesunate treatment. J Infect Dis. 2012; 207(4):687-8. DOI: 10.1093/infdis/jis736. View

Li X, Bjorkman A, Andersson T, Ridderstrom M, Masimirembwa C . Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002; 300(2):399-407. DOI: 10.1124/jpet.300.2.399. View

J Marwa K, Schmidt T, Sjogren M, Minzi O, Kamugisha E, Swedberg G . Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J. 2014; 13:420. PMC: 4228099. DOI: 10.1186/1475-2875-13-420. View

Staehli Hodel E, Csajka C, Ariey F, Guidi M, Kabanywanyi A, Duong S . Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother. 2012; 57(2):950-8. PMC: 3553711. DOI: 10.1128/AAC.01700-12. View

Rajman I, Knapp L, Morgan T, Masimirembwa C . African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development. EBioMedicine. 2017; 17:67-74. PMC: 5360579. DOI: 10.1016/j.ebiom.2017.02.017. View

Penas-Lledo E, Teran E, Sosa-Macias M, Galaviz-Hernandez C, Gil J, Nair S . Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences-Ibero-American Network of Pharmacogenetics and Pharmacogenomics.... Clin Ther. 2020; 42(8):1595-1610.e5. DOI: 10.1016/j.clinthera.2020.06.008. View

Paganotti G, Gramolelli S, Tabacchi F, Russo G, Modiano D, Coluzzi M . Distribution of human CYP2C8*2 allele in three different African populations. Malar J. 2012; 11:125. PMC: 3353233. DOI: 10.1186/1475-2875-11-125. View

Adjei G, Kristensen K, Goka B, Hoegberg L, Alifrangis M, Rodrigues O . Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother. 2008; 52(12):4400-6. PMC: 2592852. DOI: 10.1128/AAC.00673-07. View

Yates A, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J . Ensembl 2020. Nucleic Acids Res. 2019; 48(D1):D682-D688. PMC: 7145704. DOI: 10.1093/nar/gkz966. View

10.

Parikh S, Ouedraogo J, Goldstein J, Rosenthal P, Kroetz D . Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007; 82(2):197-203. DOI: 10.1038/sj.clpt.6100122. View

11.

Greenwood B . New tools for malaria control - using them wisely. J Infect. 2017; 74 Suppl 1:S23-S26. DOI: 10.1016/S0163-4453(17)30187-1. View

12.

Rower S, Bienzle U, Weise A, Lambertz U, Forst T, Otchwemah R . Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health. 2005; 10(12):1271-3. DOI: 10.1111/j.1365-3156.2005.01525.x. View

13.

Kudzi W, Dodoo A, Mills J . Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet. 2009; 10:124. PMC: 3224726. DOI: 10.1186/1471-2350-10-124. View

14.

Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem M, Dahoma M, Ribeiro V . CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol. 2005; 61(1):15-8. DOI: 10.1007/s00228-004-0871-8. View

15.

Adehin A, Bolaji O, Kennedy M . Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population. Drug Metab Pharmacokinet. 2017; 32(3):189-191. DOI: 10.1016/j.dmpk.2016.09.001. View

16.

Strom G, Tellevik M, Hanevik K, Langeland N, Blomberg B . Comparison of four methods for extracting DNA from dried blood on filter paper for PCR targeting the mitochondrial Plasmodium genome. Trans R Soc Trop Med Hyg. 2014; 108(8):488-94. PMC: 4096016. DOI: 10.1093/trstmh/tru084. View

17.

Cavaco I, Piedade R, Gil J, Ribeiro V . CYP2C8 polymorphism among the Portuguese. Clin Chem Lab Med. 2006; 44(2):168-70. DOI: 10.1515/CCLM.2006.030. View

18.

Arnaldo P, Thompson R, Lopes M, Suffys P, Santos A . Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population. Malays J Med Sci. 2013; 20(4):13-23. PMC: 3773348. View

19.

Tornio A, Backman J . Cytochrome P450 in Pharmacogenetics: An Update. Adv Pharmacol. 2018; 83:3-32. DOI: 10.1016/bs.apha.2018.04.007. View

20.

Russom M, Tesfai D, Gebregiorgis S, Usman A, Mihreteab S, Bahta I . Artesunate/Amodiaquine-Induced Acute Extrapyramidal Reactions in Children and Younger Adults: Case Series Assessment. Drug Saf. 2016; 39(8):763-8. DOI: 10.1007/s40264-016-0429-6. View